Erik Harms1, Bernhard Olgemöller. 1. Klinik für Kinder- und Jugendmedizin – Allgemeine Pädiatrie – der Westfä -lischen Wilhelms-Universität Münster. harms@uni-muenster.de
Abstract
BACKGROUND: Neonatal screening for treatable endocrinopathies and inborn errors of metabolism is an important preventive measure. Advances in the diagnosis and treatment of these diseases have made it necessary to expand the screening program. METHODS: This article is based on a selective literature review and our clinical experience. RESULTS: In 2005, neonatal screening in Germany was expanded from 3 to 14 diseases, as mandated by the responsible governmental authority (the Gemeinsamer Bundesausschuss, i.e., Joint Federal Committee). From 2005 to 2008, screening revealed diseases requiring treatment in 1932 out of a total of 2,758,633 newborns (prevalence, 1 in 1428). The expansion of the screening program resulted in a 57% increase in the overall number of cases detected and a 92% increase for metabolic diseases alone. CONCLUSION: The German neonatal screening program for treatable endocrinopathies and inborn errors of metabolism is a complex and integrated preventive measure that has become markedly more effective as a result of its expansion in 2005.
BACKGROUND: Neonatal screening for treatable endocrinopathies and inborn errors of metabolism is an important preventive measure. Advances in the diagnosis and treatment of these diseases have made it necessary to expand the screening program. METHODS: This article is based on a selective literature review and our clinical experience. RESULTS: In 2005, neonatal screening in Germany was expanded from 3 to 14 diseases, as mandated by the responsible governmental authority (the Gemeinsamer Bundesausschuss, i.e., Joint Federal Committee). From 2005 to 2008, screening revealed diseases requiring treatment in 1932 out of a total of 2,758,633 newborns (prevalence, 1 in 1428). The expansion of the screening program resulted in a 57% increase in the overall number of cases detected and a 92% increase for metabolic diseases alone. CONCLUSION: The German neonatal screening program for treatable endocrinopathies and inborn errors of metabolism is a complex and integrated preventive measure that has become markedly more effective as a result of its expansion in 2005.
Authors: Jacques Sarles; Patrice Berthézène; Christian Le Louarn; Claude Somma; Jean-Marc Perini; Michael Catheline; Sophie Mirallié; Karine Luzet; Michael Roussey; Jean-Pierre Farriaux; Jacques Berthelot; Jean-Charles Dagorn Journal: J Pediatr Date: 2005-09 Impact factor: 4.406
Authors: R J Pollitt; A Green; C J McCabe; A Booth; N J Cooper; J V Leonard; J Nicholl; P Nicholson; J R Tunaley; N K Virdi Journal: Health Technol Assess Date: 1997 Impact factor: 4.014
Authors: A Grüters; F Delange; G Giovannelli; M Klett; P Rochiccioli; T Torresani; D Grant; O Hnikova; J Maenpää; G F Rondanini Journal: Eur J Pediatr Date: 1993-12 Impact factor: 3.183
Authors: Claudia Frömmel; Annemarie Brose; Jeannette Klein; Oliver Blankenstein; Stephan Lobitz Journal: Biomed Res Int Date: 2014-07-23 Impact factor: 3.411
Authors: Álvaro Martín-Rivada; Laura Palomino Pérez; Pedro Ruiz-Sala; Rosa Navarrete; Ana Cambra Conejero; Pilar Quijada Fraile; Ana Moráis López; Amaya Belanger-Quintana; Elena Martín-Hernández; Marcello Bellusci; Elvira Cañedo Villaroya; Silvia Chumillas Calzada; María Teresa García Silva; Ana Bergua Martínez; Sinziana Stanescu; Mercedes Martínez-Pardo Casanova; Miguel L F Ruano; Magdalena Ugarte; Belén Pérez; Consuelo Pedrón-Giner Journal: JIMD Rep Date: 2022-01-27